Seguimento angiográfico e clínico tardio do novo stent farmacológico n？o-polimérico liberador de paclitaxel para o tratamento de les？es coronárias de novo: resultados do estudo PAX-B

background: the non-polymeric paclitaxel-eluting sent amazonia？ pax did not show differences in the occurrence of coronary restenosis or clinical events after 4 months of follow-up when compared with the taxus？ stent. however, the performance of the amazonia？ pax stent in more complex cases and with longer angiographic follow-up has not been demonstrated. methods: the pax-b study was a prospective, non-randomized, multicenter study assessing the late follow-up of patients treated with the amazonia？ pax stent. the primary outcome was in-stent late lumen loss. results: one hundred and three patients with mean age of 61.3 ± 11.4 years were included, 26.2% were diabetics, 24.3% had acute coronary syndromes and 71.6% had type b2/c lesions. multiple stents were performed in 4.7% of the cases and angiographic success was 100%. during hospitalization, the periprocedural acute myocardial infarction rate was 3.9% and one of these events led to target lesion revascularization (tlr). at 9-month angiographic follow-up, the median in-stent late lumen loss was 0.91 [0.50; 1.21] mm. the cumulative rates of major adverse cardiac events at the 6-month, 9-month and 12-month follow-up were 7.8%, 18.5% and 21.3%, respectively, mostly due to tlr. there was no death or stent thrombosis at 12 months. conclusions: the stent amazonia？ pax demonstrated excellent immediate results and high safety profile. however, angiographic recurrence rates were relatively high, due to low efficacy in inhibition of neointimal hyperplasia.